Effect of Phellinus Polysaccharide on Canonical Wnt Signaling in Synovium in Rats with Rheumatoid Arthritis

MIAO Cheng-gui, ZHOU Guo-liang, QIN Mei-song. et al

Abstract

To investigate the role of Phellinus Polysaccharide (PPS) in activating canonical Wnt signaling in rats with rheumatoid arthritis (RA). Methods Male SD rats were randomly divided into three groups (normal group, RA model group and PPS treated RA group), each with 10 rats. The RA model rats were prepared through intradermal injection of 0.1 mL complete Freund’s adjuvant into the right rear toes of the rats. The PPS treated RA rats were given 50 mg/kg PPS by gavage eight days after the introduction of RA. All rats were evaluated with arthritis score and paw swelling score at day 16, 20, 24, 28, 32. At day 28, the expressions of fibronectin gene, Wnt signal pathway negative regulation gene SFRP1,2 and Wnt key gene β-catenin, C-myc, and ccnd1 were detected by real time qPCR. Results PPS significantly reduced the arthritis score and paw swelling score of RA model rats. Lower levels of expression of SFRP1,2 and higher levels of expression of β-catenin, C-myc, ccnd1 and fibronectin were found in the RA model rats compared with the normal controls. PPS increased the expression of SFRP1,2 and decreased the expression of β-catenin, C-myc, ccnd1 and fibronectin in the RA rats. Conclusion PPS has significant therapeutic effect on RA model rats through inhibiting canonical Wnt signaling.

 

Keywords: Phellinus polysaccharide, Rheumatoid arthritis, Canonical, Wnt signaling β-catenin 


Full Text:

PDF


References


Huang YJ, Shiau AL, Chen SY, et al. Multivalent structure of galectin-l-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering. Eur Cell Mater,2012; 13(23): 170-181.

Tedesco A, D’ Agostino D, Soriente I, et al. A new strategy for the early diagnosis of rheumatoid arthritis; a combined approach. Autoimmun Rev,2009;8(3): 233-237.

Miao CG, Yang YY, He X, et al. Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling. Cell Signal,2013;25( 10):2069-2078.

Sen M, Reifert J, Lauterbach K, et al. Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum,2002;46 (11): 2867-2877.

Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther, 2008; 117(6): 244-279.

Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factoralpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol» 2006; 3 (2) :220-228.

Feldmann M, Brennan FM, Williams RO, et al. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol,2004; 18(8):59-80.

Stock M, Bohm C, Scholtysek C, et al. Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor ormediated experimental arthritis. Arthritis Rheum , 2013;65(9):2310-2322.

Lories RJ. Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol,2013;9(6) :328- 339.

Lazarova DL, Chiaro C, Bordonaro M. Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells. BMC Res Notes, 2014 ; 7; 226. doi: 10. 1186/1756- 0500-7-226.


Refbacks

  • There are currently no refbacks.